As biotech investors continue to wait for Arena Pharmaceuticals to launch its obesity drug Belviq, pharmaceutical company Vivus (NASDAQ: VVUS ) has been trying to ramp up sales for its rival drug Qsymia. The company's slow drug launch has been the topic of much debate in past quarters, but it recently reported that its total number of prescriptions shipped in March were 42% greater than scripts in January. Should investors be excited about this result, or will the real catalyst for this stock be its upcoming earnings report for the first quarter of 2013? Health-care analyst Max Macaluso sheds light on this topic in the following video.
Is now the time to sell VIVUS?
VIVUS' shares were clobbered after Qsymia's dismal launch. Investors everywhere are wondering whether the tide will turn for this fledgling drugmaker or if now is the perfect time to sell. In a new premium research report, the Fool's top health-care contributor breaks down this complex story and explains the details VIVUS investors must know -- including reasons to buy and sell. To find out more about this premium report click here now.